Review Reports
- Sabrina Ceccariglia 1,
- Diego Sibilia 1,2 and
- Fabrizio Pizzolante 5,*
- et al.
Reviewer 1: Anonymous Reviewer 2: Anonymous
Round 1
Reviewer 1 Report
Comments and Suggestions for AuthorsThe manuscript entitled “Endothelial VEGFR-2 Activation Precedes Severe Mucosal Injury in TNBS-Induced Colitis” investigates VEGFR-2 phosphorylation and Akt activation in TNBS-induced colitis. The topic is potentially interesting; however, several issues should be addressed before the Major Comments
- Abstract
The abstract suddenly introduces AKT1 without sufficient background or explanation. The rationale for examining AKT signaling should be briefly clarified. The results section of the abstract is overly descriptive. The conclusion stating that “TNBS-induced colitis is associated with early VEGFR-2 phosphorylation and Akt activation occurring prior to severe mucosal injury” is not fully supported by the presented data. The authors should clarify whether both VEGFR-2 phosphorylation and Akt activation consistently occur before severe mucosal injury and provide stronger evidence supporting this conclusion.
- Introduction
The introduction is generally well written. However, the authors do not clearly explain why Akt was selected as a downstream signaling target. Additional rationale and relevant literature should be included to justify the focus on Akt signaling in this study.
- Results
2.1.1. Macroscopic and Histological Evaluation
Presenting only a single representative image is insufficient and does not adequately support the findings. More representative images from multiple samples should be provided.
2.1.2. Macrophage Infiltration
Similarly, additional representative images corresponding to the reported sample numbers should be included.
The sample sizes are inconsistent between groups (e.g., one group with n = 3 and another with n = 4). The authors should explain the reason for this discrepancy.
Figures
The presentation of Figure 3 and Figure 5 is problematic. In some panels, error bars are not visible. The authors should carefully verify the raw data and figure preparation, otherwise the accuracy and reliability of the data may be questioned.
Since the statistical methods are already described in the Materials and Methods section, there is no need to repeatedly restate them in the Results section.
- Discussion
The content in lines 229–233 appears to be more appropriate for the Introduction section rather than the Discussion.
References to figures such as “(Figure 3A)” should not be repeatedly included in the Discussion section.
In general, the Discussion should remain more focused on interpreting the actual results of the study. Currently, some parts appear overly speculative or somewhat disconnected from the presented data.
- Materials and Methods
This section is generally detailed and well organized. However, some descriptions are unnecessarily repetitive and could be simplified. For example, statements such as “control rats (n = 3) and TNBS-treated animals (4 days, n = 4)” are repeated multiple times and could be streamlined for clarity and conciseness.
Overall, the manuscript addresses an interesting topic, but substantial revisions are necessary to improve the rigor of the data presentation and the clarity of the interpretation.nuscript can be considered for publication.
Author Response
The manuscript entitled “Endothelial VEGFR-2 Activation Precedes Severe Mucosal Injury in TNBS-Induced Colitis” investigates VEGFR-2 phosphorylation and Akt activation in TNBS-induced colitis. The topic is potentially interesting; however, several issues should be addressed before the Major CommentsThe manuscript entitled “Endothelial VEGFR-2 Activation Precedes Severe Mucosal Injury in TNBS-Induced Colitis” investigates VEGFR-2 phosphorylation and Akt activation in TNBS-induced colitis. The topic is potentially interesting; however, several issues should be addressed before the Major Comments.
1) The abstract suddenly introduces AKT without sufficient background or explanation. The rationale for examining AKT signaling should be briefly clarified. The results section of the abstract is overly descriptive. The conclusion stating that “TNBS-induced colitis is associated with early VEGFR-2 phosphorylation and Akt activation occurring prior to severe mucosal injury” is not fully supported by the presented data. The authors should clarify whether both VEGFR-2 phosphorylation and Akt activation consistently occur before severe mucosal injury and provide stronger evidence supporting this conclusion.
We thank the Reviewer for this constructive comment. To address this concern, we have revised the Abstract (highlighted in red) to clarify the rationale for evaluating Akt signaling by explicitly indicating that Akt is a major downstream effector of VEGFR-2 signaling.
We have modified the Background, Materials and Methods, Results, and Conclusions sections of the Abstract to better reflect our findings and to avoid overinterpretation of the temporal relationship between signaling activation and tissue injury.
In addition, we have included representative histological images from days 2 and 6 following TNBS administration. These data, together with the histological analyses and inflammatory cell infiltration findings, demonstrate minimal histological alterations on day 2, moderate inflammatory and epithelial changes on day 4, and extensive mucosal destruction on day 6. Therefore, the molecular analyses performed on day 4 are placed within a well-defined stage of disease progression preceding advanced tissue damage.
We have also revised the Conclusions to indicate that VEGFR-2 phosphorylation and Akt activation are associated with an early inflammatory stage that precedes extensive mucosal destruction, rather than implying a definitive causal relationship or temporal sequence.
We believe that these revisions adequately address the Reviewer's concern and provide a more accurate interpretation of the association between VEGFR-2/Akt signaling and disease progression.
2) The introduction is generally well written. However, the authors do not clearly explain why Akt was selected as a downstream signaling target. Additional rationale and relevant literature should be included to justify the focus on Akt signaling in this study.
We thank the reviewer for this insightful comment. In response, we have revised the Introduction (Page 2, line 168, highlighted in red) to better justify our focus on Akt signaling. Specifically, we now explain that Akt is a key downstream mediator of VEGFR-2 signaling and plays a central role in endothelial cell survival, vascular permeability, angiogenesis, and inflammatory responses. Since these mechanisms are closely involved in the early vascular changes associated with IBD, this pathway represents a biologically relevant downstream target of VEGFR-2 in the context of the present study.
3) Results
3.1.1. Macroscopic and Histological Evaluation
Presenting only a single representative image is insufficient and does not adequately support the findings. More representative images from multiple samples should be provided.
We thank the Reviewer for this important comment. To better document the progression of TNBS-induced intestinal injury and support the interpretation of day 4 as an early inflammatory stage, we have expanded the macroscopic and histological evaluation by including additional representative images obtained at days 2 and 6 after TNBS administration. These additional time points illustrate the temporal evolution of tissue damage, with inconsistent alterations on day 2, moderate inflammatory changes on day 4, and more extensive tissue injury and necrosis on day 6.
The images shown were selected from multiple animals and are representative of the histopathological features consistently observed within each experimental group. Accordingly, the Results section (Page 4 line 120-146, highlighted in red) has been revised to incorporate additional macroscopic and histological findings and provide a more comprehensive description of the progression of TNBS-induced intestinal injury over time. The revised figures and text therefore offer a more complete characterization of disease progression and further support the interpretation of early VEGF-A/VEGFR-2 activation during the initial phase of intestinal inflammation.
3.1.2. Macrophage Infiltration
Similarly, additional representative images corresponding to the reported sample numbers should be included.
We thank the Reviewer for this valuable suggestion. In response, we have expanded Figure 2 by including additional representative immunofluorescence images and quantification of CD68-positive macrophages from all experimental groups (control, day 2, day 4, and day 6 TNBS-treated animals). These images provide a more comprehensive representation of macrophage infiltration across the different time points and complement the quantitative analysis reported in Figure 2E. Materials and Methods (Page 16, line 459 and 478, highlighted in red) Results (Page 5-6, lines 173-188, highlighted in red), and Discussion (Page 10, lines 309-315, highlighted in red) sections are revised.
The sample sizes are inconsistent between groups (e.g., one group with n = 3 and another with n = 4). The authors should explain the reason for this discrepancy.
We thank the Reviewer for this comment. The difference in sample size between groups was intentional and defined during the experimental design. Specifically, fewer animals were allocated to the control group (n = 3) because untreated animals are expected to exhibit limited biological variability compared with TNBS-treated animals. In contrast, TNBS-induced colitis is characterized by a more heterogeneous response among animals, which may increase data variability. Therefore, a slightly larger number of animals (n = 4) was included in the TNBS-treated groups to account for this expected variability and to ensure reliable assessment of treatment-related effects. This clarification has now been added to the Materials and Methods (Page 11, line 384, highlighted in red) section.
Figures
The presentation of Figure 3 and Figure 5 is problematic. In some panels, error bars are not visible. The authors should carefully verify the raw data and figure preparation, otherwise the accuracy and reliability of the data may be questioned.
Since the statistical methods are already described in the Materials and Methods section, there is no need to repeatedly restate them in the Results section.
We thank the reviewer for these observations. In Figures 3 and 5, data were expressed as fold change relative to the control group, which was set to 1 as specified in Paras 4.3 (line 436) and 4.5 (line 499) of the Materials and Methods section and figure legends. Consequently, error bars are not visible for the control group because the normalization procedure fixes the control value at 1. In addition, in Figure 5A where error bars are not shown in control and in TNBS group, protein expression levels were below the detection threshold in individual control samples. Therefore, as described in Para 2.2.3. of the Results section, samples were pooled prior to analysis to obtain a detectable signal. Under these conditions, the densitometric value derives from a pooled sample rather than from independent biological replicates, and consequently no measure of variability (SEM) could be calculated.
Moreover, statistical methods have been removed from the Results section and figure legends where they were unnecessarily repeated. Details regarding statistical analyses are now reported exclusively in the Materials and Methods section.
4) The content in lines 229–233 appears to be more appropriate for the Introduction section rather than the Discussion.
References to figures such as “(Figure 3A)” should not be repeatedly included in the Discussion section.
In general, the Discussion should remain more focused on interpreting the actual results of the study. Currently, some parts appear overly speculative or somewhat disconnected from the presented data.
We thank the Reviewer for this helpful comment. The text originally presented in lines 229–233 has been substantially revised (now lines 381–385, highlighted in red). Rather than providing background information, the revised paragraph now focuses on the interpretation of our findings, emphasizing the association between early endothelial activation and VEGF-A/VEGFR-2 signaling observed in TNBS-induced colitis. We believe that this revision makes the text more appropriate for the Discussion section.
We have also revised the Discussion to remove repeated references to specific figure panels (e.g., Figure 3A), retaining only general figure citations where necessary to support the interpretation of the findings.
Finally, we refined the Discussion (lines 436–442 and 457–463, highlighted in red) to better distinguish data-supported findings from broader biological interpretations, reducing overly speculative language regarding VEGF-A/VEGFR-2 signaling, the cellular source of VEGF-A, and potential translational implications. The revised Discussion now focuses more directly on the experimental observations and their interpretation.
5) Materials and Methods
This section is generally detailed and well organized. However, some descriptions are unnecessarily repetitive and could be simplified. For example, statements such as “control rats (n = 3) and TNBS-treated animals (4 days, n = 4)” are repeated multiple times and could be streamlined for clarity and conciseness.
We thank the Reviewer for this helpful suggestion. We have carefully revised the Materials and Methods section to remove unnecessary repetitions and improve overall readability. Repeated descriptions of experimental groups (e.g., control and TNBS-treated animals and their corresponding sample sizes) have been streamlined throughout the manuscript. These revisions improve clarity and conciseness while preserving all relevant methodological details.
Reviewer 2 Report
Comments and Suggestions for AuthorsThe manuscript presents interesting evidence supporting activation of the VEGF-A/VEGFR-2 signaling axis during TNBS-induced colitis, including increased VEGF-A and VEGFR-2 expression, receptor phosphorylation, downstream Akt activation, and enhanced macrophage infiltration at day 4.
General comments
These findings support an association between endothelial signaling and intestinal inflammation. However, the current data do not fully establish whether endothelial VEGFR-2 activation is an initiating event or a secondary response to ongoing inflammation, contrary to what they said they had established. A major challenge in interpreting causality arises from the fact that day 4 tissues already exhibit clear epithelial injury, edema, and substantial macrophage infiltration, indicating that inflammation is already well established at the selected time point. Therefore, it remains difficult to conclude that endothelial activation precedes inflammatory initiation rather than occurring because of epithelial damage and immune cell recruitment. This point is further complicated by the fact that VEGF-A may originate from multiple cellular sources, including infiltrating macrophages, epithelial cells, stromal cells, and endothelial cells themselves, as acknowledged by the authors. Since macrophage infiltration is already increased at day 4, it remains possible that macrophage-derived VEGF-A contributes to VEGFR-2 activation rather than endothelial activation, representing the primary initiating event (which would therefore not represent the initial cause).
To better support the proposed temporal sequence, assessment of earlier time points before evident epithelial injury and macrophage infiltration would be valuable. Alternatively, the authors should moderate conclusions regarding endothelial activation as an early driver of inflammation and discuss these limitations more explicitly. However, in that case, the paper would become less interesting, as this is already partly known.
Further experiments addressing the involvement of the VEGF-A/VEGFR-2 signaling axis are necessary to support the authors’ conclusions. This is particularly important because the current dataset remains limited, both mechanistically and in terms of the overall volume of experimental work expected for a research article. This concern is further compounded by the fact that Figure 1 would be more appropriately placed in the supplementary material, leaving limited primary experimental data.
Specific comments
- Line 90: Day 4 was selected as the main experimental time point (which should be reformulated by the way), it would be helpful to present comparative information from days 2 and 6 to better justify this choice. And hopefully find the cause, initial steps.
- Line 102: Histopathological evaluation was described; however, no histological scoring system or quantitative assessment was provided. Clarification of the evaluation criteria would strengthen this section.
- Line 137: The data support increased macrophage infiltration (CD68-positive cells), but not necessarily macrophage activation. The term “activation” may require additional supporting evidence or alternatively be at least justified by referring to previous work demonstrating that macrophages are mostly activated under these conditions.
- Evaluation of disease severity parameters (e.g., body weight changes or DAI) at the selected time point would help contextualize the inflammatory stage analyzed.
- The relatively small sample size (CTRL, n = 3; TNBS, n = 4) may limit the robustness of the conclusions. Validation in an additional cohort, or preferably demonstration of similar findings in a complementary colitis model, would strengthen confidence in the reproducibility and generalizability of the results.
Author Response
General comments
These findings support an association between endothelial signaling and intestinal inflammation. However, the current data do not fully establish whether endothelial VEGFR-2 activation is an initiating event or a secondary response to ongoing inflammation, contrary to what they said they had established. A major challenge in interpreting causality arises from the fact that day 4 tissues already exhibit clear epithelial injury, edema, and substantial macrophage infiltration, indicating that inflammation is already well established at the selected time point. Therefore, it remains difficult to conclude that endothelial activation precedes inflammatory initiation rather than occurring because of epithelial damage and immune cell recruitment. This point is further complicated by the fact that VEGF-A may originate from multiple cellular sources, including infiltrating macrophages, epithelial cells, stromal cells, and endothelial cells themselves, as acknowledged by the authors. Since macrophage infiltration is already increased at day 4, it remains possible that macrophage-derived VEGF-A contributes to VEGFR-2 activation rather than endothelial activation, representing the primary initiating event (which would therefore not represent the initial cause).
To better support the proposed temporal sequence, assessment of earlier time points before evident epithelial injury and macrophage infiltration would be valuable. Alternatively, the authors should moderate conclusions regarding endothelial activation as an early driver of inflammation and discuss these limitations more explicitly. However, in that case, the paper would become less interesting, as this is already partly known.
Further experiments addressing the involvement of the VEGF-A/VEGFR-2 signaling axis are necessary to support the authors’ conclusions. This is particularly important because the current dataset remains limited, both mechanistically and in terms of the overall volume of experimental work expected for a research article. This concern is further compounded by the fact that Figure 1 would be more appropriately placed in the supplementary material, leaving limited primary experimental data.
We thank the Reviewer for this important observation. We agree that the original version may have overstated the causal interpretation of endothelial VEGFR-2 activation. To address this concern, we have substantially revised both the Results and Discussion sections. Specifically, we included additional temporal characterization at days 2 and 6, allowing a clearer contextualization of the selected day-4 time point as a transitional stage between the absence of overt tissue alterations and the development of severe mucosal injury. Furthermore, we have moderated our conclusions throughout the manuscript and now explicitly state that the present data demonstrate an association between early intestinal inflammation and VEGF-A/VEGFR-2 signaling activation, without establishing a direct causal role or temporal precedence of endothelial activation. We have also clarified that the cellular source of VEGF-A was not investigated and therefore no conclusions can be drawn regarding the relative contribution of macrophages or other cell populations. These revisions are reflected in the Results (paras 2.1.1 and 2.1.2), Discussion (lines 399-406) with Conclusions (lines 499-505) sections (highlighted in red).
Specific comments
- Line 90: Day 4 was selected as the main experimental time point (which should be reformulated by the way), it would be helpful to present comparative information from days 2 and 6 to better justify this choice. And hopefully find the cause, initial steps.
We thank the Reviewer for this comment. To better justify the selection of day 4 as the main experimental time point, we have included additional analyses at days 2 and 6 after TNBS administration in the revised manuscript (Results sections 2.1.1 and 2.1.2 and Discussion lines 445-448, highlighted in red). These new data demonstrate that day 2 is characterized by the absence of relevant macroscopic and histological alterations, whereas day 6 shows severe colonic injury, including extensive mucosal necrosis and marked disruption of tissue architecture. Together, these findings support the interpretation of day 4 as a transitional phase between early and advanced stages of TNBS-induced colitis, representing the onset of overt inflammatory and tissue alterations. Accordingly, we have revised the wording in the manuscript to better reflect this temporal characterization and to clarify the rationale for selecting this time point.
- Line 102: Histopathological evaluation was described; however, no histological scoring system or quantitative assessment was provided. Clarification of the evaluation criteria would strengthen this section.
We thank the Reviewer for this valuable comment. In response, we have revised the manuscript to include a detailed description of the histopathological scoring system in the Results (page 12, line 252-256, highlighted in red), Materials and Methods (page 17, lines 556-563, highlighted in red) and in the Statistical Analysis (lines 655-656, highlighted in red) sections. In addition, a new table (Table 1., page 5) summarizing the scoring criteria has been added to improve clarity and reproducibility. Histological damage was assessed using a semiquantitative scoring system evaluating epithelial damage, inflammatory cell infiltration, edema, crypt destruction, and lesion extent, each graded on a scale from 0 to 3 according to severity. The overall histological score was calculated as the sum of the individual parameters. These revisions improve the transparency and reproducibility of the histological assessment.
- Line 137: The data support increased macrophage infiltration (CD68-positive cells), but not necessarily macrophage activation. The term “activation” may require additional supporting evidence or alternatively be at least justified by referring to previous work demonstrating that macrophages are mostly activated under these conditions.
We thank the Reviewer for this important observation. We agree that CD68 immunostaining primarily reflects macrophage infiltration rather than direct assessment of macrophage activation. In response, we have revised the manuscript to remove any overinterpretation of the term “activation” and to more accurately describe the observed findings as increased macrophage infiltration in Results (page 6 lines 303-309, highlighted in red) and Discussion (page 10, lines 450-456, highlighted in red) sections. We have also added references from previous studies using the TNBS-induced colitis model, which report elevated levels of pro-inflammatory cytokines such as TNF-α and IL-1β, consistent with a pro-inflammatory environment in which macrophage activation may occur. Accordingly, the text has been modified to ensure that no direct conclusions regarding macrophage activation are drawn from CD68 immunostaining alone.
- Evaluation of disease severity parameters (e.g., body weight changes or DAI) at the selected time point would help contextualize the inflammatory stage analyzed.
We thank the Reviewer for this helpful suggestion. Body weight changes were evaluated throughout the experimental protocol to further characterize disease severity. TNBS-treated rats exhibited a progressive reduction in body weight, averaging approximately 0-1% on day 2, 5-6% on day 4, and 8-9% on day 6 compared with baseline values. These findings are consistent with the progression of acute TNBS-induced colitis and support the inflammatory stages analyzed at the selected time points. This information has now been included in the Results (page 4, lines 257-260, highlighted in red) and in Materials and Methods (page 11, lines 520-521, highlighted in red).
- The relatively small sample size (CTRL, n = 3; TNBS, n = 4) may limit the robustness of the conclusions. Validation in an additional cohort, or preferably demonstration of similar findings in a complementary colitis model, would strengthen confidence in the reproducibility and generalizability of the results.
We thank the Reviewer for this valuable comment. We have revised the Limitations paragraph in the Discussion to explicitly acknowledge that the relatively small sample size (CTRL, n = 3; TNBS, n = 4) may limit statistical power and generalizability of the findings (lines 483-484, highlighted in red). Importantly, the observed effects were consistent across multiple independent readouts within our experimental framework, supporting the robustness of the findings despite the limited sample size (lines 484–485). We also note that similar sample sizes are commonly reported in TNBS-induced colitis studies and have been shown to be sufficient to detect consistent and reproducible biological effects, as supported by the literature now cited in the revised manuscript (lines 485–488).
- The relatively small sample size (CTRL, n = 3; TNBS, n = 4) may limit the robustness of the conclusions. Validation in an additional cohort, or preferably demonstration of similar findings in a complementary colitis model, would strengthen confidence in the reproducibility and generalizability of the results.
We thank the Reviewer for this valuable comment. We have revised the Limitations paragraph in the Discussion to explicitly acknowledge that the relatively small sample size (CTRL, n = 3; TNBS, n = 4) may limit statistical power and generalizability of the findings (lines 483-484, highlighted in red). Importantly, the observed effects were consistent across multiple independent readouts within our experimental framework, supporting the robustness of the findings despite the limited sample size (lines 484–485). We also note that similar sample sizes are commonly reported in TNBS-induced colitis studies and have been shown to be sufficient to detect consistent and reproducible biological effects, as supported by the literature now cited in the revised manuscript (lines 485–488).
Round 2
Reviewer 1 Report
Comments and Suggestions for AuthorsThe authors are encouraged to carefully review the revised manuscript, which has been submitted in track-changes mode and remains somewhat difficult to assess. For instance, in the Abstract, the Results section appears to contain only a single sentence; please verify that no content has been inadvertently removed during revision.
Furthermore, references to figures throughout the Discussion section are unnecessary and repetitive. The Discussion should primarily focus on the interpretation and significance of the findings rather than reiterating figure citations.
Finally, several figure legends still contain the same problem. The phrase “control rats (n = 3) and TNBS-treated animals (4 days, n = 4)” is repeated multiple times.
Author Response
“The authors are encouraged to carefully review the revised manuscript, which has been submitted in track-changes mode and remains somewhat difficult to assess”.
We thank the Reviewer for this comment. The revised manuscript has been carefully checked, and the track-changes mode has been removed. All modifications made in response to the reviewers’ comments are now clearly highlighted in red to facilitate evaluation.
“In the Abstract, the Results section appears to contain only a single sentence; please verify that no content has been inadvertently removed during revision.”
We thank the Reviewer for this comment. No content was inadvertently removed. However, the Results section of the Abstract has been expanded to provide a more complete summary of the main findings, including histological injury and macrophage infiltration in TNBS-induced colitis.
“Furthermore, references to figures throughout the Discussion section are unnecessary and repetitive. The Discussion should primarily focus on the interpretation and significance of the findings rather than reiterating figure citations.”
We thank the Reviewer for this suggestion. References to figures have been removed throughout the Discussion section to improve readability and to focus the text on the interpretation and significance of the findings rather than on figure citation.
“Finally, several figure legends still contain the same problem. The phrase “control rats (n = 3) and TNBS-treated animals (4 days, n = 4)” is repeated multiple times.”
We thank the Reviewer for this observation. The repeated description of the experimental groups and sample sizes has been removed from the figure legends to avoid redundancy. These details are already provided in the Results and Materials and Methods sections.